• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Purcell Michael J. returned 139,322 shares to the company, closing all direct ownership in the company (SEC Form 4)

    11/14/23 9:02:19 PM ET
    $TRHC
    Business Services
    Consumer Discretionary
    Get the next $TRHC alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
    X
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Purcell Michael J.

    (Last) (First) (Middle)
    228 STRAWBRIDGE DRIVE

    (Street)
    MOORESTOWN NJ 08057

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Tabula Rasa HealthCare, Inc. [ TRHC ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    11/03/2023
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 11/03/2023 D 88,514 D (1) 50,808 D
    Common Stock 11/03/2023 D 50,808 D (2) 0 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Upon the consummation of the merger (the "Merger") contemplated by that certain Agreement and Plan of Merger, by and among Tabula Rasa HealthCare, Inc. (the "Company"), Locke Buyer, LLC and Locke Merger Sub, Inc., dated August 5, 2023 (the "Merger Agreement"), 88,514 shares of common stock of the Company ("Common Stock") were converted into the right to receive a cash payment of $929,397, representing the product obtained by multiplying (x) the number of shares of Common Stock owned by the reporting person, by (y) the offer price ($10.50).
    2. Upon the consummation of the Merger, pursuant to the Merger Agreement, 50,808 unvested restricted stock awards ("RSAs") were cancelled and converted into the right to receive a cash payment of $533,484, representing the product obtained by multiplying (x) the aggregate number of shares of Common Stock underlying the RSAs, by (y) the offer price ($10.50).
    /s/ Brian W. Adams, by Power of Attorney 11/14/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $TRHC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TRHC

    DatePrice TargetRatingAnalyst
    5/10/2023$7.00 → $10.00Market Perform → Outperform
    SVB Securities
    3/2/2022$30.00 → $15.00Buy
    Benchmark
    2/28/2022$23.00 → $11.00Market Perform
    SVB Leerink
    2/1/2022$24.00 → $11.00Outperform → Neutral
    Robert W. Baird
    2/1/2022$24.00 → $11.00Outperform → Neutral
    Baird
    12/2/2021$13.00Hold
    Jefferies
    11/8/2021$70.00 → $23.00Outperform
    RBC Capital
    11/8/2021$40.00 → $23.00Market Perform
    SVB Leerink
    More analyst ratings

    $TRHC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Mitchell Ronald Paul returned 79,332 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Tabula Rasa HealthCare, Inc. (0001651561) (Issuer)

      11/14/23 9:09:01 PM ET
      $TRHC
      Business Services
      Consumer Discretionary
    • Purcell Michael J. returned 139,322 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Tabula Rasa HealthCare, Inc. (0001651561) (Issuer)

      11/14/23 9:02:19 PM ET
      $TRHC
      Business Services
      Consumer Discretionary
    • Schwartz Jonathan David returned 78,388 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Tabula Rasa HealthCare, Inc. (0001651561) (Issuer)

      11/14/23 8:59:36 PM ET
      $TRHC
      Business Services
      Consumer Discretionary

    $TRHC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Tabula Rasa HealthCare upgraded by SVB Securities with a new price target

      SVB Securities upgraded Tabula Rasa HealthCare from Market Perform to Outperform and set a new price target of $10.00 from $7.00 previously

      5/10/23 6:30:40 AM ET
      $TRHC
      Business Services
      Consumer Discretionary
    • Benchmark reiterated coverage on Tabula Rasa HealthCare with a new price target

      Benchmark reiterated coverage of Tabula Rasa HealthCare with a rating of Buy and set a new price target of $15.00 from $30.00 previously

      3/2/22 7:40:57 AM ET
      $TRHC
      Business Services
      Consumer Discretionary
    • SVB Leerink reiterated coverage on Tabula Rasa HealthCare with a new price target

      SVB Leerink reiterated coverage of Tabula Rasa HealthCare with a rating of Market Perform and set a new price target of $11.00 from $23.00 previously

      2/28/22 4:58:06 AM ET
      $TRHC
      Business Services
      Consumer Discretionary

    $TRHC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Lifshitz Law PLLC Announces Investigations of VRTV, FRGI, TRHC, and SOVO

      NEW YORK, Aug. 12, 2023 (GLOBE NEWSWIRE) -- Veritiv Corporation (NYSE:VRTV) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of VRTV to an affiliate of Clayton, Dubilier & Rice, LCC for $170.00 per share in cash for each share of VRTV common stock owned. If you are a VRTV investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected]. Fiesta Restaurant Group, Inc. (NASDAQ:FRGI) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary dutie

      8/12/23 8:17:00 PM ET
      $FRGI
      $SOVO
      $TRHC
      $VRTV
      Restaurants
      Consumer Discretionary
      Packaged Foods
      Consumer Staples
    • Tabula Rasa HealthCare Reports Second Quarter 2023 Financial Results

      Continued Strong Organic Revenue Growth of 24% Second Quarter Adjusted EBITDA of $6.3 Million Increased More Than 3x Compared to Second Quarter 2022 MOORESTOWN, N.J., Aug. 7, 2023 /PRNewswire/ -- Tabula Rasa HealthCare, Inc.® (NASDAQ:TRHC) ("TRHC" or the "Company"), a leading healthcare company advancing personalized, comprehensive care for value-based care organizations, today reported financial results for the second quarter ended June 30, 2023. Highlights from the second quarter ended June 30, 2023 include: Second quarter revenue from continuing operations of $90.0 million

      8/7/23 7:02:00 AM ET
      $TRHC
      Business Services
      Consumer Discretionary
    • Tabula Rasa and ExactCare to Combine to Create a Leading, Independent Pharmacy Care Management Company That Services Patients with the Most Complex Needs

      $10.50 Per Share All-Cash Transaction Represents a Significant Premium for Tabula Rasa Stockholders Combination of Two Highly Complementary Companies to Benefit Patients, Providers and Payers with First of its Kind Risk Management Platform in Pharmacy Care Expands the Reach of Tabula Rasa's MedWise Technology Platform to Multiple Provider and Payer Markets MOORESTOWN, N.J., Aug. 7, 2023 /PRNewswire/ -- Tabula Rasa HealthCare, Inc.® ("TRHC," "Tabula Rasa" or the "Company") (NASDAQ:TRHC), a leading healthcare company advancing personalized, comprehensive care for value-based care organizations, today announced it has entered into a definitive agreement (the "Agreement") to be acquired by Nauti

      8/7/23 7:00:00 AM ET
      $TRHC
      Business Services
      Consumer Discretionary

    $TRHC
    SEC Filings

    See more
    • SEC Form EFFECT filed by Tabula Rasa HealthCare Inc.

      EFFECT - Tabula Rasa HealthCare, Inc. (0001651561) (Filer)

      11/17/23 12:15:07 AM ET
      $TRHC
      Business Services
      Consumer Discretionary
    • SEC Form EFFECT filed by Tabula Rasa HealthCare Inc.

      EFFECT - Tabula Rasa HealthCare, Inc. (0001651561) (Filer)

      11/17/23 12:15:26 AM ET
      $TRHC
      Business Services
      Consumer Discretionary
    • SEC Form EFFECT filed by Tabula Rasa HealthCare Inc.

      EFFECT - Tabula Rasa HealthCare, Inc. (0001651561) (Filer)

      11/17/23 12:15:13 AM ET
      $TRHC
      Business Services
      Consumer Discretionary